Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,452 | 539 | 2,853 |
| Samples | 1,125 | 244 | 860 |
| Peptides | 959 | 175 | 792 |
Function
LRBA · LPS responsive beige-like anchor protein
The protein encoded by this gene is a member of the WDL-BEACH-WD (WBW) gene family. Its expression is induced in B cells and macrophages by bacterial lipopolysaccharides (LPS). The encoded protein associates with protein kinase A and may be involved in leading intracellular vesicles to activated receptor complexes, which aids in the secretion and/or membrane deposition of immune effector molecules. Defects in this gene are associated with the disorder common variable immunodeficiency-8 with autoimmunity. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2012].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000357115 | P50851 | 1,160 | 895 |
| ENST00000510413 | P50851-2 | 1,138 | 876 |
| ENST00000507224 | E9PEM5* | 1,018 | 786 |
| ENST00000651943 | A0A494C1L5* | 136 | 129 |
Gene Properties
Recurrent Mutations
All 895 amino-acid changes on canonical ENST00000357115 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LRBA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LRBA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 5/25 20% | 0/0 0% |
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Oral Cavity Carcinoma | 6/54 11% | 0/0 0% |
| Endometrial Carcinoma | 13/42 31% | 52/612 8% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Glioblastoma | 7/98 7% | 0/0 0% |
| Melanoma | 16/210 8% | 129/1899 7% |
| Unknown | 2/10 20% | 0/29 0% |
| Non-Small Cell Lung Carcinoma | 38/304 12% | 46/1390 3% |
| Squamous Cell Lung Carcinoma | 10/57 18% | 27/810 3% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Other Solid Cancers | 7/94 7% | 53/1515 4% |
| Cervical Carcinoma | 1/35 3% | 16/422 4% |
| Bladder Carcinoma | 6/58 10% | 30/956 3% |
| Plasma Cell Myeloma | 6/44 14% | 6/305 2% |
| Colorectal Carcinoma | 25/143 17% | 89/3239 3% |
| Gastric Carcinoma | 5/74 7% | 52/1809 3% |
| Neuroendocrine Tumour | 11/154 7% | 11/577 2% |
| Hodgkins Lymphoma | 2/16 12% | 2/122 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 19/752 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Thyroid Gland Carcinoma | 4/45 9% | 30/1592 2% |
| Germ Cell Tumour | 2/25 8% | 2/169 1% |
| Other Sarcomas | 1/69 1% | 13/699 2% |
| Head and Neck Carcinoma | 5/85 6% | 23/1574 1% |
| Breast Carcinoma | 14/144 10% | 42/3264 1% |
| Ovarian Carcinoma | 2/109 2% | 16/998 2% |
| Biliary Tract Carcinoma | 1/54 2% | 15/950 2% |
| Glioma | 2/52 4% | 32/2127 2% |
Mutation Distribution
Where LRBA is mutated · all tissues, split by cell line vs tissue
How many mutations in LRBA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,452 mutations in LRBA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|